

LINK-J ネットワーキング・ナイト WITH SUPPORTERS

英国における産官学連携と バイオベンチャーの成功事例

Insights into UK technology transfer collaborations and
a case study of a successful biotech spin-out company

2017年 **11月2日(木)**

開催言語：英語

18:00 - 21:00 (受付開始 17:30)

@ 日本橋ライフサイエンスビルディング 10階 1004会議室 (予定)

ライフサイエンス分野を中心に多くの新技術を発明している英国では、大学 TLO という機能が早くに成熟した国でもあり、国外とのアライアンスを含め、新技術とビジネスが密接につながっています。今回は「英国における産官学連携の事例とバイオベンチャーの成功事例」と題して、英国から4名の講師を迎えます。



Prof. Ludovic Vallier

ケンブリッジ大学再生医療研究所

最新のヒト iPS 細胞から分化させた肺・小腸・肝臓・膵臓細胞への誘導メカニズムおよび機能について学術的な説明と共に、Vallier 氏の研究成果がどのような形でビジネスの世界に還元されて来たか、ライセンスアウトの事例を講演します。



Dr. Marcus Yeo

DefiniGEN

大学における飛びぬけた技術を発掘し、投資を集め事業を創設した経緯と、ヒト iPS 細胞から分化誘導させた疾患モデル細胞がグローバルファーマにてどのように活用されているか、各種事例を紹介します。



Dr. Tim Hart

オックスフォード大学産学連携機構 (OUI)

ライフサイエンスに関する学術的成果や発明をビジネス化する橋渡しを行った事例や、ベンチャー企業への初期投資を含めた戦略の立て方等について説明します。



Griff Jones

英国大使館科学技術部

英国におけるライフサイエンス研究の強みと産業の活性化について、政府の立場からどのようなサポート体制を構築してきたか、通称ミッション等のケーススタディもあわせて紹介します。



津田 真吾 氏

LINK-J サポーター

INDEE Japan / INDEE Medical

【登壇者プロフィール / Profiles】

Prof. Ludovic Vallier (ケンブリッジ大学再生医療研究所 / Professor, Laboratory for Regenerative Medicine, University of Cambridge)

Ludovic graduated in Molecular biology and Immunology from the University Claude Bernard Lyon I in 1997. In 2001, he earned his PhD at Ecole Normale Supérieure of Lyon in the group of Jacques Samarut, under the supervision of Pierre Savatier, studying mechanisms that control the cell cycle in mouse embryonic stem (ES) cells. Following a year in the biotechnology industry, Ludovic joined Professor Pedersen's group at the University of Cambridge Department of Surgery. In 2008 he joined the newly opened Anne McLaren Laboratory for Regenerative Medicine (LRM) as a Principal Investigator. He heads two key research groups at the Sanger Centre and University of Cambridge studying mechanisms of liver, pancreatic, lung and intestinal differentiation.

Dr. Marcus Yeo (Chief Executive Officer, DefiniGEN)

Marcus is an experienced Company Director and life scientist who took the Oxford-based diagnostics biotechnology company Cybersense Biosystems Ltd to acquisition in 2008 by the FTSE 100 company Severn Trent. He oversaw the integration of the business into the Severn Trent ISO 17025 structure and led sales and marketing of the Severn Trent analytics division. Marcus previously worked for the University of Oxford company Zyoxel Ltd (now CN Bio Innovations), which markets advanced 3D human tissue culture systems to the investigative toxicology drug discovery sector. He specialised in the development of next-generation stem cell derived liver toxicology products and disease modelling systems for drug discovery lead optimisation. He has a PhD in Molecular Biology and is an accredited European Commission Technology Expert who has managed in excess of £15m of R&D funding.

Dr. Tim Hart (オックスフォード大学産学連携機構 / Managing Consultant, Oxentia, Oxford University Innovation Ltd.)

Tim has gained 25 years' experience in technology commercialisation, particularly from university environments, and in the life sciences. He has worked as an academic researcher, technology transfer professional, and entrepreneur, having spun-out and managed two investment-backed life science companies from university research. He brings particular sector leading expertise in academic entrepreneurship. His experience is truly international, having worked for and with some of the largest technology corporates and leading universities across Asia, Russia, Europe, North and South America, Australia, and Africa.

Griff Jones (英国大使館科学技術部 / First Secretary Head of Science, Innovation and Global Challenges)

Griff previously worked at the Department for Business, Energy and Industrial Strategy and its predecessor the Department for Business, Innovation and Science between 2013 and 2017. His main responsibilities were for higher education regulatory reform, health higher education workforce reform and latterly areas of international cooperation on research and innovation.

In 2012 Griff worked for the New Zealand Government for a year on science and innovation strategy at the Ministry of Business, Innovation and Employment. Prior to this between 2005 and 2011 he held posts in the UK at the Department for Communities and Local Government and the Department of Health. This included a period as a minister's private secretary.

津田 真吾 氏 (INDEE Japan 代表取締役テクニカルディレクター・INDEE Medical 取締役 / Co-founder and Technical Director, INDEE Japan Ltd. Director, INDEE Medical Inc.)

Shingo Tsuda

Cofounded INDEE Japan, an accelerator for innovation projects after R&D experience at IBM. Also cofounded ZENTECH DOJO Nihonbashi, a hands-on seed accelerator program mainly focusing on lifesciences. Holds 18 patents in various fields. BE, Waseda Univ.

【プログラム / Program】

- 18:00 - 開会挨拶 (津田氏) / Opening remarks
- 18:10 - プレゼンテーション / Presentations
- 19:50 - パネルディスカッション / Panel discussion
- 20:10 - 懇親会 (軽食) / Reception (snacks)
- 21:00 閉会 / Closings

【会費 / Fee】

- LINK-J Supporter / Member : 500 Yen
- LINK-J Non-member : 2,000 Yen

※LINK-J サポーター・会員の方は、割引コードをお伝えしますので、LINK-J までご連絡ください。(E-mail: contact@link-j.org)

*For LINK-J supporters and members please contact LINK-J for discount code (E-mail: contact@link-j.org)

【申し込み先 / Registration】 事前申込み制 / Pre-registration is required

<http://peatix.com/event/284998>



【アクセス / Access】

日本橋ライフサイエンスビルディング 10 階 1004 会議室 / 10F., Nihonbashi Life Science Building. Rm1004

※開場は申し込み人数により変更となる場合がございます。The venue might change depending on the number of registrants.

〒103-0023 東京都中央区日本橋本町 2-3-11

(東京メトロ銀座線・半蔵門線「三越前」A6 出口より徒歩 3 分、

JR 総武線「新日本橋」駅 5 出口より徒歩 2 分)

※ご来場には公共交通機関をご利用ください。

Nihonbashi Honcho, Chuo-ku, Tokyo, 103-0023

(3-minute walk from Mitsukoshimae Station Exit A6, 2-minute

walk from Shin-Nihonbashi Station Exit 5)

※We recommend to use public transportation.